| Hope & Healing Llc | |
|
429 N Franklin St Madisonville KY 42431-1730 | |
| (270) 836-1179 | |
| Not Available |
| Full Name | Hope & Healing Llc |
|---|---|
| Speciality | Psychologist |
| Location | 429 N Franklin St, Madisonville, Kentucky |
| Authorized Official Name and Position | Rita Harpool (OWNER/PSYCHOLOGIST) |
| Authorized Official Contact | 2708361179 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Hope & Healing Llc 429 N Franklin St Madisonville KY 42431-1730 Ph: (270) 836-1179 | Hope & Healing Llc 429 N Franklin St Madisonville KY 42431-1730 Ph: (270) 836-1179 |
| NPI Number | 1205451937 |
|---|---|
| Provider Enumeration Date | 06/09/2020 |
| Last Update Date | 06/09/2020 |
| Certification Date | 06/09/2020 |
| Medicare PECOS PAC ID | 3173942026 |
|---|---|
| Medicare Enrollment ID | O20200928001006 |
News Archive
Professor Nick Macklon of Southampton University says even though most women now understand there is "overwhelming evidence" that smoking during pregnancy is harmful to the developing child, they continue to do so.
The economics of producing biopharmaceuticals from transgenic plants such as tobacco is still a roadblock to producing large quantities of urgently needed medicines, especially for people in underdeveloped nations.
At the end of the two-month comment period on the "morning-after pill" Plan B, there is no indication when or how the Food and Drug Administration will proceed with the controversial application.
Being transparent about the results of completed clinical trials enables important advances in the development of medical products and helps ensure a safe, effective and efficient clinical research enterprise.
Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205451937 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | (* (Not Available)) | Primary |
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | (* (Not Available)) | Secondary |
| Provider Name | Rita M Harpool |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1245407170 PECOS PAC ID: 2264429885 Enrollment ID: I20040427000619 |
News Archive
Professor Nick Macklon of Southampton University says even though most women now understand there is "overwhelming evidence" that smoking during pregnancy is harmful to the developing child, they continue to do so.
The economics of producing biopharmaceuticals from transgenic plants such as tobacco is still a roadblock to producing large quantities of urgently needed medicines, especially for people in underdeveloped nations.
At the end of the two-month comment period on the "morning-after pill" Plan B, there is no indication when or how the Food and Drug Administration will proceed with the controversial application.
Being transparent about the results of completed clinical trials enables important advances in the development of medical products and helps ensure a safe, effective and efficient clinical research enterprise.
Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60.
› Verified 5 days ago
| Provider Name | Linda Ball |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346323250 PECOS PAC ID: 0345309720 Enrollment ID: I20081030000674 |
News Archive
Professor Nick Macklon of Southampton University says even though most women now understand there is "overwhelming evidence" that smoking during pregnancy is harmful to the developing child, they continue to do so.
The economics of producing biopharmaceuticals from transgenic plants such as tobacco is still a roadblock to producing large quantities of urgently needed medicines, especially for people in underdeveloped nations.
At the end of the two-month comment period on the "morning-after pill" Plan B, there is no indication when or how the Food and Drug Administration will proceed with the controversial application.
Being transparent about the results of completed clinical trials enables important advances in the development of medical products and helps ensure a safe, effective and efficient clinical research enterprise.
Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60.
› Verified 5 days ago
News Archive
Professor Nick Macklon of Southampton University says even though most women now understand there is "overwhelming evidence" that smoking during pregnancy is harmful to the developing child, they continue to do so.
The economics of producing biopharmaceuticals from transgenic plants such as tobacco is still a roadblock to producing large quantities of urgently needed medicines, especially for people in underdeveloped nations.
At the end of the two-month comment period on the "morning-after pill" Plan B, there is no indication when or how the Food and Drug Administration will proceed with the controversial application.
Being transparent about the results of completed clinical trials enables important advances in the development of medical products and helps ensure a safe, effective and efficient clinical research enterprise.
Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60.
› Verified 5 days ago
Caris Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 108 S Main St Ste 104, Madisonville, KY 42431 Phone: 270-681-2273 | |
Ohio Valley Neurology Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 Clinic Dr, Madisonville, KY 42431 Phone: 270-825-6601 Fax: 270-825-7352 | |
Trover Center For Behavioral Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 630 N Franklin St, Madisonville, KY 42431 Phone: 270-825-7355 | |
Synergy Counseling And Wellness Center, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 14 N Main St, Madisonville, KY 42431 Phone: 270-245-2205 | |
Dynamic Behavior Solutions, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2325 Ridgewood Dr, Madisonville, KY 42431 Phone: 270-339-0127 | |
Get Set Go Health & Wellness Company Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 18 N Main St, Madisonville, KY 42431 Phone: 270-875-4332 |